8th Joint Conference of the International Cytokine Society (ICS) and Internationa

描述(申请人提供)：在过去的30年里，广泛的研究证实了干扰素和其他细胞因子在健康和疾病中的重要性。一些细胞因子参与发育、调节先天免疫、控制正常造血和其他重要的细胞和生物学功能，在这些领域的知识积累很快。多学科论坛将更好地了解疾病的机制和治疗的新概念，在这些论坛上，现有的和实习的科学家可以介绍和讨论进展。这项申请的总体目标是为参加2010年两大国际学会联合年会的初级研究员提供支持，这两个学会致力于细胞因子介导的免疫宿主调节在健康和疾病中的作用：国际细胞因子学会和国际干扰素和细胞因子研究学会。这次会议将于2010年10月3-7日在芝加哥举行，题为“细胞因子在传染病、自身免疫紊乱和癌症中的作用”。这一活动联合了两个学会的生物医学专业知识和精力，已成为世界上最重要的细胞因子基础和临床研究年度会议。最近在里斯本、蒙特利尔和维也纳举行了年度会议。2010年联合学会会议(细胞因子2010)将把两个学会的所有成员聚集在一起，以最大限度地促进互动和促进合作。本次会议的目标是： 具体目标1：促进青年研究人员和受训人员与细胞因子和干扰素研究领域的知名研究人员互动，并为他们介绍工作提供一个论坛。 具体目标2：促进召开一次会议，吸引来自学术和政府机构以及工业界的科学家，讨论细胞因子和干扰素在传染病、自身免疫性疾病和癌症中的作用的最新进展。演讲将由特邀演讲者和从提交的摘要中挑选的演讲者进行口头和海报演示。 具体目标3：促进制定一项计划，在下列主题下重点介绍细胞因子和/或干扰素领域最重要的研究进展和进展：炎症、T细胞生物学/获得性免疫、信号转导、IL-1生物学、免疫调节、传染病、微生物模式识别、免疫细胞发育和分化中的细胞因子、细胞因子检测的新方法、微型RNA和转录后调节、疾病治疗中的干扰素、恶性肿瘤治疗中的新治疗靶点、细胞因子和细胞死亡、阻断细胞因子反应的病毒机制、细胞因子和传染病；干扰素与病毒感染、细胞因子/趋化因子及其受体、结构/功能和基于细胞因子的治疗。 具体目标4：使任职人数不足的少数群体和残疾人能够参加一次会议，以促进与各自领域的其他科学家的互动。

DESCRIPTION (provided by applicant): Extensive work over the last 3 decades has established the importance of interferons and other cytokines in health and disease. Several cytokines are implicated in development, regulation of innate immunity, control of normal hematopoiesis and other important cellular and biological functions, and there is rapid accumulation of knowledge in these areas. Greater understanding of mechanisms of disease and novel concepts for therapy will emerge from multi-disciplinary forums where advances can be presented and discussed by established and trainee scientists. The overall objective of this application is to obtain support for junior investigator attendance to the 2010 joint annual meeting of the two major international Societies addressing cytokine-mediated immune host modulation in health and disease: International Cytokine Society and the International Society of Interferon and Cytokine Research. The conference is entitled, "Cytokines in Infectious Diseases, Autoimmune Disorders and Cancer," to be held in Chicago, October 3-7, 2010. This event unites the biomedical expertise and energies of the two societies and has become the world's most important annual conference on basic and clinical research on cytokines. Recent annual meetings were held in Lisbon, Montreal and Vienna. The 2010 joint society meeting (Cytokines 2010) will bring together all members of both Societies to maximize interactions and foster collaborations. The goals of this meeting are: Specific Aim 1: To facilitate interactions of young investigators and trainees with well-established researchers in the cytokine and interferon research fields and to provide a forum for them to present their work. Specific Aim 2: To facilitate the development of a meeting that will attract scientists from academic and governmental institutions and from industry to discuss recent advances on the roles of cytokines and interferons in infectious diseases, autoimmune disorders and cancer. Oral and poster presentations will be made by both invited speakers as well as speakers selected from submitted abstracts. Specific Aim 3: To facilitate the development of a program which highlights the most important research developments and advances in the cytokine and/or interferon fields under the subject headings: inflammation, T cell biology/adaptive immunity, signal transduction, IL-1 biology, immunoregulation, infectious diseases, microbial pattern recognition, cytokines in immune cell development and differentiation, novel methods in cytokine detection, micro-RNAs and post-transcriptional regulation, interferons in the treatment of diseases, novel therapeutic targets in the treatment of malignancies, cytokines and cell death, viral mechanisms that block cytokine responses, cytokines and infectious diseases; interferons and viral infections, cytokines/chemokines and their receptors, structure/function and cytokine-based therapies. Specific Aim 4: To enable under-represented minorities and persons with disabilities to participate in a meeting that facilitates interactions with other scientists in their fields.